The history of Alzheimer’s research has been filled with setback
after setback – in fact nearly every clinical trial has failed – but it
is also one marked by perseverance and renewed hope. Advancements in
medical imaging have increased our understanding of how the disease
strikes, and efforts are underway to develop diagnostics to treat the
disease before its onset.
With a growing aging population, how will the disease burden the
country’s health care system? The Atlantic will gather leading experts
and key stakeholders for a national conversation on what it will take to
disrupt Alzheimer’s disease.
Where
Chez
247 East Ontario Street
Chicago, IL 60611
When
Wednesday, September 12, 2018
8:00 AM - 10:30 AM CDT
Speakers
- Peter Anastasiou, executive vice president, head of North America, Lundbeck
- Samantha Budd Haeberlein, vice president, Alzheimer’s late stage clinical development, Biogen
- Daisy Duarte, caregiver, clinical trial participant, and advocate for LatinosAgainstAlzheimer’s
- Sarita Gupta, co-executive director, Jobs with Justice; co-director, Caring Across Generations
- Harry Johns, president and CEO, Alzheimer’s Association
- Elli Kaplan, co-founder and CEO, Neurotrack
- William Klein, professor, department of neurobiology, Northwestern University
- Juliet Holt Klinger, senior director, dementia care, Brookdale Senior Living
- Jill Lesser, president, WomenAgainstAlzheimer’s
- Stephanie Monroe, executive director, AfricanAmericansAgainstAlzheimer's
- Jay Newton-Small, co-founder, MemoryWell
- George Vradenburg, chairman and co-founder, UsAgainstAlzheimer's
- Johan Luthman, vice president and head of clinical development, Global Neurology Business Group, Eisai
- Rep. Bill Foster (D-IL)